Balancing Pipeline Potential and Funding Risk: Justifying a Buy Rating on Medicus Despite Extended Timelines

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Medicus Pharma Ltd. The associated price target was lowered to $2.00.

Jason McCarthy has given his Buy rating due to a combination of factors that, in his view, outweigh the extended development timelines and related capital needs. He sees SkinJect’s positive Phase 2 results in basal cell carcinoma, the planned End-of-Phase 2 FDA meeting, and the Orphan Drug Designation application in Gorlin syndrome as key value drivers that could ultimately support attractive pricing and market exclusivity.

At the same time, he views Teverelix as a second, meaningful asset, with a Phase 2b study cleared to proceed in advanced prostate cancer and additional development plans in indications such as benign prostatic hyperplasia and women’s health. While he has reduced the 12‑month price target to $2.00 to reflect later commercialization and anticipated dilution, he believes the current valuation already discounts much of this risk, leaving room for upside as Medicus secures funding, advances its trials, and potentially adds partners to share development costs.

In another report released on April 21, Roth MKM also initiated coverage with a Buy rating on the stock with a $9.00 price target.

MDCX’s price has also changed dramatically for the past six months – from $2.700 to $0.314, which is a -88.37% drop .